AstraZeneca Pharma [ASTRAZEN] vs Cipla [CIPLA] Detailed Stock Comparison

AstraZeneca Pharma

NSE
Loading...

Cipla

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: AstraZeneca Pharma wins in 4 metrics, Cipla wins in 16 metrics, with 0 ties. Cipla appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricAstraZeneca PharmaCiplaBetter
P/E Ratio (TTM)123.4322.85Cipla
Price-to-Book Ratio29.923.92Cipla
Debt-to-Equity Ratio4.641.40Cipla
PEG Ratio-0.222.24AstraZeneca Pharma
EV/EBITDA79.3315.81Cipla
Profit Margin (TTM)9.88%19.62%Cipla
Operating Margin (TTM)12.26%22.31%Cipla
EBITDA Margin (TTM)12.26%22.31%Cipla
Return on Equity15.02%16.85%Cipla
Return on Assets (TTM)7.62%14.10%Cipla
Free Cash Flow (TTM)$636.10M$34.57BCipla
Dividend Yield0.34%1.72%Cipla
1-Year Return25.47%5.43%AstraZeneca Pharma
Price-to-Sales Ratio (TTM)12.434.48Cipla
Enterprise Value$225.55B$1,121.31BCipla
EV/Revenue Ratio12.164.08Cipla
Gross Profit Margin (TTM)43.87%68.25%Cipla
Revenue per Share (TTM)$742$340AstraZeneca Pharma
Earnings per Share (Diluted)$74.70$66.22AstraZeneca Pharma
Beta (Stock Volatility)0.170.10Cipla
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

AstraZeneca Pharma vs Cipla Stock Performance Analysis

Loading Price Chart...

AstraZeneca Pharma
Cipla
AstraZeneca Pharma Stock Overview | Cipla Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
AstraZeneca Pharma1.18%5.90%2.59%2.41%15.65%29.67%
Cipla0.31%1.22%-3.85%0.60%1.47%2.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
AstraZeneca Pharma25.47%200.62%119.03%689.02%790.41%2,521.07%
Cipla5.43%34.25%88.97%120.10%350.09%934.00%

News Based Sentiment: AstraZeneca Pharma vs Cipla

AstraZeneca Pharma

News based Sentiment: POSITIVE

The primary event of the month was a 2.6% increase in AstraZeneca Pharma India Ltd.'s stock price on October 1, 2025. This positive movement, with a high of ₹9150 and a low of ₹8852.45, suggests a strengthening of investor confidence and a potentially favorable outlook for the company.

View AstraZeneca Pharma News Sentiment Analysis

Cipla

News based Sentiment: MIXED

Cipla reported strong financial results in Q1 and Q2 of FY 2025-26, alongside improvements in its balance sheet. However, the stock is currently considered overvalued based on fundamental analysis, creating a mixed investment outlook. External factors like the Pfizer-US deal also introduce moderate risks.

View Cipla News Sentiment Analysis

Performance & Financial Health Analysis: AstraZeneca Pharma vs Cipla

MetricASTRAZENCIPLA
Market Information
Market Cap i₹233.48B₹1.22T
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i15,3811,500,344
90 Day Avg. Volume i18,9371,204,696
Last Close₹9,331.00₹1,517.70
52 Week Range₹6,220.00 - ₹10,691.00₹1,335.00 - ₹1,607.80
% from 52W High-12.72%-5.60%
All-Time High₹10,691.00 (Jun 13, 2025)₹1,607.80 (Aug 25, 2025)
% from All-Time High-12.72%-5.60%
Growth Metrics
Quarterly Revenue Growth0.36%0.03%
Quarterly Earnings Growth0.36%0.10%
Financial Health
Profit Margin (TTM) i0.10%0.20%
Operating Margin (TTM) i0.12%0.22%
Return on Equity (TTM) i0.15%0.17%
Debt to Equity (MRQ) i4.641.40
Cash & Liquidity
Book Value per Share (MRQ)₹308.14₹386.24
Cash per Share (MRQ)₹214.46₹131.44
Operating Cash Flow (TTM) i₹-2,319,700,000₹55.16B
Levered Free Cash Flow (TTM) i₹1.16B₹52.73B
Dividends
Last 12-Month Dividend Yield i0.34%1.72%
Last 12-Month Dividend i₹32.00₹26.00

Valuation & Enterprise Metrics Analysis: AstraZeneca Pharma vs Cipla

MetricASTRAZENCIPLA
Price Ratios
P/E Ratio (TTM) i123.4322.85
Forward P/E iN/A23.81
PEG Ratio i-0.222.24
Price to Sales (TTM) i12.434.48
Price to Book (MRQ) i29.923.92
Market Capitalization
Market Capitalization i₹233.48B₹1.22T
Enterprise Value i₹225.55B₹1.12T
Enterprise Value Metrics
Enterprise to Revenue i12.164.08
Enterprise to EBITDA i79.3315.81
Risk & Other Metrics
Beta i0.170.10
Book Value per Share (MRQ) i₹308.14₹386.24

Financial Statements Comparison: AstraZeneca Pharma vs Cipla

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ASTRAZENCIPLA
Revenue/Sales i₹5.26B₹68.37B
Cost of Goods Sold i₹2.95B₹21.71B
Gross Profit i₹2.31B₹46.66B
Research & Development iN/AN/A
Operating Income (EBIT) i₹645.40M₹15.25B
EBITDA i₹923.50M₹20.37B
Pre-Tax Income i₹747.00M₹17.70B
Income Tax i₹188.70M₹4.78B
Net Income (Profit) i₹558.30M₹12.92B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ASTRAZENCIPLA
Cash & Equivalents i₹5.36B₹5.89B
Total Current Assets i₹13.42B₹232.89B
Total Current Liabilities i₹7.03B₹54.84B
Long-Term Debt i₹294.50M₹2.52B
Total Shareholders Equity i₹7.70B₹312.89B
Retained Earnings i₹6.33B₹256.44B
Property, Plant & Equipment i₹635.80M₹52.62B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ASTRAZENCIPLA
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricASTRAZENCIPLA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i15,3811,500,344
Average Daily Volume (90 Day) i18,9371,204,696
Shares Outstanding i25.00M807.62M
Float Shares i4.14M562.88M
% Held by Insiders i0.82%0.31%
% Held by Institutions i0.06%0.41%

Dividend Analysis & Yield Comparison: AstraZeneca Pharma vs Cipla

MetricASTRAZENCIPLA
Last 12-Month Dividend i₹32.00₹26.00
Last 12-Month Dividend Yield i0.34%1.72%
3-Year Avg Annual Dividend i₹24.00₹16.00
3-Year Avg Dividend Yield i0.37%0.76%
3-Year Total Dividends i₹72.00₹48.00
Ex-Dividend DateJul 18, 2025Jun 27, 2025